Recently, T cell-targeted monoclonal antibodies such as the anti-IL-17A agent secukinumab, anti-CD4 monoclonal antibody, and cytotoxic T lymphocyte-associated antigen 4-immunoglobulin have demonstrated significant therapeutic efficacy in the treatment of psoriasis [13]. The gene discussed is CD4; the disease is psoriasis.